Citigroup Inc. Boosts Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Citigroup Inc. lifted its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 251.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 387,226 shares of the biotechnology company's stock after purchasing an additional 277,138 shares during the period. Citigroup Inc. owned 0.17% of ADMA Biologics worth $7,741,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its stake in shares of ADMA Biologics by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company's stock worth $48,007,000 after purchasing an additional 249,412 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of ADMA Biologics during the third quarter worth approximately $1,242,000. Jennison Associates LLC acquired a new position in ADMA Biologics in the 3rd quarter valued at $690,000. New Millennium Group LLC acquired a new position in shares of ADMA Biologics in the third quarter valued at about $4,139,000. Finally, Aviance Capital Partners LLC acquired a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $229,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Finally, Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th.

Insider Transactions at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The trade was a 5.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Trading Down 7.9 %

Shares of ADMA Biologics stock traded down $1.72 on Friday, reaching $20.11. 4,002,265 shares of the company's stock were exchanged, compared to its average volume of 3,622,850. The firm's 50-day moving average is $19.08 and its two-hundred day moving average is $15.31. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a market capitalization of $4.75 billion, a P/E ratio of 71.82 and a beta of 0.64. ADMA Biologics, Inc. has a 52 week low of $3.60 and a 52 week high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. During the same period in the previous year, the business earned $0.01 earnings per share. Sell-side analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.